By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Astellas Pharma US 

1 Astellas Way

Northbrook  Illinois  60062  U.S.A.
Phone: 800-695-4321 Fax: n/a






Gilead (Seattle, WA) 

Company News
Astellas Pharma US Release: Results Of Open-Label Trial For CRESEMBA (isavuconazonium sulfate) Treatment Of Invasive Mucormycosis Published In The Lancet Infectious Diseases 3/9/2016 6:30:57 AM
Astellas Pharma US Release: Lancet Publishes Results From The Phase 2 TERRAIN Trial of enzalutamide Compared To bicalutamide In Metastatic Castration-Resistant Prostate Cancer 1/14/2016 7:02:52 AM
Astellas Pharma US Provides Update On Phase 3 Study Evaluating Isavuconazole In Patients With Candidemia And Other Invasive Candida Infections 7/30/2015 11:44:27 AM
Astellas Pharma US Release: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 5/18/2015 6:35:05 AM
Astellas Pharma US Release: CRESEMBA (Isavuconazonium Sulfate) Data To Be Presented At The European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2015 12:30:24 PM
Astellas Pharma US And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 4/22/2015 11:05:38 AM
Astellas Pharma US Teams Up With The Chris Klug Foundation On The Bounce Back Award To Recognize Extraordinary Transplant Recipients 4/2/2015 7:33:41 AM
Astellas Pharma US Release: New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress 3/17/2015 10:04:13 AM
Astellas Pharma US And (BDO) Team Up To Offer Health Education At The 2015 CIAA Tournament Fan Fest 2/20/2015 1:37:13 PM
Astellas Pharma US Release: XTANDI™ (Enzalutamide) Now Approved In Europe For The Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Na├»ve 12/2/2014 9:16:16 AM